Won Dong Kim
Overview
Explore the profile of Won Dong Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1046
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moon J, Park J, Lee K, Park D, Yoo G, Choi C, et al.
Int J Radiat Biol
. 2025 Jan;
101(3):283-291.
PMID: 39792988
Purpose: We aimed to identify the transcriptomic signatures of soft tissue sarcoma (STS) related to radioresistance and establish a model to predict radioresistance. Materials And Methods: Nine STS cell lines...
2.
Kim A, Lee J, Moon H, Kim C, Yoo M, Park W, et al.
Radiat Oncol J
. 2023 Jul;
41(2):89-97.
PMID: 37403351
Purpose: We aimed to determine whether low-dose radiotherapy (LDRT) is effective in patients with Alzheimer disease (AD). Materials And Methods: We included patients according to the following criteria: probable Alzheimer's...
3.
Kim D, Kim W, Kim S, Moon D, Lee S
Cell Death Dis
. 2020 May;
11(5):406.
PMID: 32471991
System x contributes to glutathione (GSH) synthesis and protects cells against ferroptosis by importing cystine and exchanging it with glutamate. Transforming growth factor β1 (TGF-β1) induces redox imbalance; however, its...
4.
Jang H, Kim D, Lee H, Kim W, Kim S, Hwang J, et al.
Biochem Pharmacol
. 2018 Dec;
160:110-120.
PMID: 30579838
Combination of MEK inhibitor and 5-FU had showed limited efficacy in clinical trials. We previously reported that acquired resistance to 5-FU was related with continued activation of salvage pathway. Here...
5.
Joo M, Kim W, Lee K, Kim J, Koo J, Kim S
Mol Cell Biol
. 2016 May;
36(14):1931-42.
PMID: 27161318
Nrf2 (nuclear factor erythroid 2-related factor 2) is an antioxidant transcription factor. AMP-activated protein kinase (AMPK) functions as a central regulator of cell survival in response to stressful stimuli. Nrf2...
6.
Kim M, Hong E, Chai J, Leem J, You I, Kim W, et al.
Cancer Res Treat
. 2015 Dec;
35(4):330-4.
PMID: 26680955
Purpose: The outcomes of a surgical approach for patients with an esophageal carcinoma remain unsatisfactory despite its high complication rates. We conducted a phase II trial, using combined FP (5-fluorouracil...
7.
Sohn H, Kim S, Ahn J, Kang H, Park S, Jung H, et al.
Cancer Res Treat
. 2015 Dec;
34(6):409-15.
PMID: 26680896
Purpose: s: Although the standard management of limited stage small cell lung cancer is concurrent platinum-based chemotherapy with thoracic radiotherapy (TRT), the optimal timing of the TRT remains controversial. We...
8.
Lee S, Choi E, Oh S, Suh C, Kim S, Lee J, et al.
Cancer Res Treat
. 2015 Dec;
34(5):345-51.
PMID: 26680886
Purpose: To investigate the feasibility, toxicity and response rate, of concurrent chemoradiation therapy with paclitaxel/cisplatin in stage III locally advanced non-small cell lung cancer (NSCLC). Materials And Methods: Between May...
9.
Kim H, Kim K, Bea S, Jin Oh S, Lee K, Kim W, et al.
Cancer Res Treat
. 2015 Dec;
34(4):296-301.
PMID: 26680879
Purpose: The combination of chemotherapy and radiotherapy is emerging as the new standard modality for the treatment of locally advanced head and neck cancer, due to the inherent functional and...
10.
Discovery of an integrative network of microRNAs and transcriptomics changes for acute kidney injury
Lee C, Kim J, Kim H, Kwon H, Cho I, Choi D, et al.
Kidney Int
. 2014 Apr;
86(5):943-53.
PMID: 24759152
The contribution of miRNA to the pathogenesis of acute kidney injury (AKI) is not well understood. Here we evaluated an integrative network of miRNAs and mRNA data to discover a...